Geron Stops Phase 3 Imetelstat Trial After Committee Says Survival Benefit Is Unlikely

Geron Corporation: IMPACT-MF Study Discontinuation May Not Be So Disastrous (NASDAQ:GERN)

With the MF label expansion closed, Geron Corporation will focus on maximizing Rytelo's approved lower-risk MDS indication. I rate the GERN stock as Hold. Click to know more.

Geron Stops Phase 3 Imetelstat Trial After Committee Says Survival Benefit Is Unlikely

Geron is discontinuing its Phase 3 IMpactMF trial of imetelstat after an independent committee found it unlikely to improve overall survival in relapsed or refractory myelofibrosis.

Investigators Discontinue Phase 3 Trial of Imetelstat in R/R Myelofibrosis

The phase 3 IMpactMF study will be discontinued after an independent committee determined it was unlikely to meet its primary end point of overall survival.